摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Benzyloxycarbonyl-4-hydroxy-4-(2-benzyloxyphenyl)-piperidine | 161609-77-4

中文名称
——
中文别名
——
英文名称
1-Benzyloxycarbonyl-4-hydroxy-4-(2-benzyloxyphenyl)-piperidine
英文别名
1-benzyloxycarbonyl-4-hydroxy-4-(2-benzyloxyphenyl)piperidine;benzyl 4-hydroxy-4-(2-phenylmethoxyphenyl)piperidine-1-carboxylate
1-Benzyloxycarbonyl-4-hydroxy-4-(2-benzyloxyphenyl)-piperidine化学式
CAS
161609-77-4
化学式
C26H27NO4
mdl
——
分子量
417.505
InChiKey
NGVFPUFBUXCNJN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    31
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    59
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    1-Benzyloxycarbonyl-4-hydroxy-4-(2-benzyloxyphenyl)-piperidine 生成 1-Benzyloxycarbonyl-4-(2-benzyloxyphenyl)piperidine
    参考文献:
    名称:
    Aryl substituted heterocycles
    摘要:
    本发明涉及下面列出的式I的芳基取代杂环化合物的新用途,这些化合物拮抗一种内源性神经肽激肽素和神经激肽2(NK2)受体的药理作用,使其在需要这种拮抗作用的情况下非常有用,例如在治疗哮喘和相关疾病时。该发明还提供了含有这些芳基取代杂环化合物的药物组合物,用于这种治疗。还提供了某些新型的式I的芳基取代杂环化合物以及用于它们制备的新型中间体。
    公开号:
    US05654299A1
  • 作为产物:
    参考文献:
    名称:
    Aryl substituted heterocycles
    摘要:
    本发明涉及下面列出的式I的芳基取代杂环化合物的新用途,这些化合物拮抗一种内源性神经肽激肽素和神经激肽2(NK2)受体的药理作用,使其在需要这种拮抗作用的情况下非常有用,例如在治疗哮喘和相关疾病时。该发明还提供了含有这些芳基取代杂环化合物的药物组合物,用于这种治疗。还提供了某些新型的式I的芳基取代杂环化合物以及用于它们制备的新型中间体。
    公开号:
    US05654299A1
点击查看最新优质反应信息

文献信息

  • Cyclic amide derivatives for treating asthma
    申请人:Zeneca Limited
    公开号:US05589489A1
    公开(公告)日:1996-12-31
    Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.
    式I的化合物##STR1##其中Q.sup.1、Q.sup.2、Q.sup.3和Q.sup.4具有规范中给定的任意含义,它们的N-氧化物以及它们的药用盐是神经激肽A的非肽拮抗剂,可用于治疗哮喘等。还公开了制药组合物、制备式I化合物和中间体的方法。
  • [EN] N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS<br/>[FR] NAPHTALENE CARBOXAMIDES N-SUBSTITUES EN TANT QU'ANTAGONISTES DE RECEPTEURS DES NEUROKININES
    申请人:ZENECA LTD
    公开号:WO2000002859A1
    公开(公告)日:2000-01-20
    A compound of formula (I) wherein: R is alkyl; R1 is optionally substituted phenyl, 2-oxo-tetrahydro-1(2H)-pyrimidinyl, or 2-oxo-1-piperidinyl; R2 is hydrogen, alkoxy, alkanoyloxy, alkoxycarbonyl, alkanoylamino, acyl, alkyl, carbamoyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl where the alkyl groups are the same or different, hydroxy, thioacyl, thiocarbamoyl, N-alkylthiocarbamoyl, or N,N-dialkylthiocarbamoyl where the alkyl groups are the same or different. X¿1? and X2 are independently hydrogen or halo, provided that at least one of X1 or X2 is halo; and R?3, R4, R5, and R6¿ are independently hydrogen, cyano, nitro, trifluoromethoxy, trifluoromethyl, or alkylsulfonyl are antagonists of at least one tachykinin receptor and are useful in the treatment of depression, anxiety, asthma, pain, inflammation, urinary incontinence and other disease conditions. Processes for their preparation are described, as are compositions containing them and their use.
    化合物的化学式(I),其中:R为烷基; R1为可选取代的苯基,2-氧代-四氢-1(2H)-嘧啶基或2-氧代-1-哌啶基; R2为氢、烷氧基、烷酰氧基、烷氧羰基、烷酰胺、烷基、氨基甲酰、N-烷基氨基甲酰、N,N-二烷基氨基甲酰,其中烷基团相同或不同,羟基、硫代酰基、硫代氨基、N-烷基硫代氨基、N,N-二烷基硫代氨基,其中烷基团相同或不同。X1和X2独立地为氢或卤素,但至少其中之一为卤素; R3、R4、R5和R6独立地为氢、氰基、硝基、三氟甲氧基、三氟甲基或烷基磺酰基,是至少一种快速激动肽受体的拮抗剂,可用于治疗抑郁症、焦虑症、哮喘、疼痛、炎症、尿失禁和其他疾病。描述了它们的制备过程,以及包含它们和它们的使用的组合物。
  • N-substituted naphthalene carboxamides as neurokinin-receptor antagonists
    申请人:Astra Zeneca AB
    公开号:US06365602B1
    公开(公告)日:2002-04-02
    A compound of formula I wherein: R is alkyl; R1 is optionally substituted phenyl 2-oxo-tetrahydro-1(2H)-pyrimidinyl, or 2-oxo-1-piperidinyl; R2 is hydrogen, alkoxy, alkanoyloxy, alkoxycarbonyl, alkanoylamino, acyl, alkyl, carbamoyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl where the alkyl groups are the same or different, hydroxy, thioacyl, thiocarbamoyl, N-alkylthiocarbamoyl, or N,N-dialkylthiocarbamoyl where the alkyl groups are the same or different. X1 and X2 are independently hydrogen or halo, provided that at least one of X1 or X2 is halo; and R3, R4, R5 and R6 are independently hydrogen, cyano, nitro, trifluoromethoxy, trifluoromethyl, or alkylsulfonyl are antagonists of at least one tachykinin receptor and are useful in the treatment of depression, anxiety, asthma, pain, inflammation, urinary incontinence and other disease conditions. Process for their preparation are described, as are compositions containing them and their use.
    化合物I的化学式为:其中R为烷基;R1为可选取代的苯基2-氧代四氢-1(2H)-嘧啶基,或2-氧代-1-哌啶基;R2为氢、烷氧基、烷酰氧基、烷氧羰基、烷酰胺基、酰基、烷基、氨基甲酰、N-烷基氨基甲酰、N,N-二烷基氨基甲酰(其中烷基可以相同或不同)、羟基、硫代酰基、硫代氨基甲酰、N-烷基硫代氨基甲酰或N,N-二烷基硫代氨基甲酰(其中烷基可以相同或不同)。X1和X2独立地为氢或卤素,但至少其中之一为卤素;R3、R4、R5和R6独立地为氢、氰基、硝基、三氟甲氧基、三氟甲基或烷基磺酰基,是至少一种速激肽受体的拮抗剂,可用于治疗抑郁症、焦虑症、哮喘、疼痛、炎症、尿失禁和其他疾病。描述了它们的制备过程,以及含有它们的组合物和它们的用途。
  • 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists
    申请人:ZENECA LIMITED
    公开号:EP0630887A1
    公开(公告)日:1994-12-28
    The present invention concerns the novel aryl substituted heterocycles of formula I, set out below, wherein R², R³ and R⁴ have the values defined herein, which antagonize the pharmacological actions of one of the endogenous neuropeptide tachykinins at the neurokinin 2 (NK2) receptor making them useful whenever such antagonism is desired, such as in the treatment of asthma and related conditions. The invention also provides pharmaceutical compositions containing the aryl substituted heterocycles for use in such treatment, methods for their use, and processes and novel intermediates for their manufacture.
    本发明涉及如下式 I 的新型芳基取代杂环,其中 R²、R³ 和 R⁴ 具有本文所定义的值,该杂环可拮抗内源性神经肽之一速激肽在神经激肽 2 (NK2) 受体上的药理作用,因此在需要这种拮抗作用时,例如在治疗哮喘和相关病症时,它们是有用的。 本发明还提供了用于此类治疗的含有芳基取代杂环的药物组合物、使用方法以及生产工艺和新型中间体。
  • CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS
    申请人:AstraZeneca AB
    公开号:EP0734383B1
    公开(公告)日:2002-07-24
查看更多